Palantir's stock price declined 0.50%-4.00% on trading days, driven by AI valuation concerns and a potential loss of a $441M contract with the U.K.'s National Health Service.

Palantir's stock has been under pressure, with shares trading 2.6%-3.4% below key moving averages on one trading day while also declining 26% year-to-date [doc4]. One reason for the stock's slide is a potential contract loss - the U.K.'s National Health Service may end its $441 million deal with the company by 2027 [doc6].

Another factor is broader market jitters about AI valuations, which may be impacting Palantir's valuation given its focus on artificial intelligence [doc6]. Additionally, upcoming inflation data and the pending IPO of SpaceX have likely contributed to the stock's decline. During the same period, Palantir made efforts to position itself in the market with a recent partnership expansion with Google Cloud, making its services available on Google Cloud Marketplace [doc4].

Analysts maintain a favorable outlook on the stock, with most keeping a buy rating and estimating an average target price of $189.38. Palantir is also gearing up for its August 3, 2026 earnings report.

The potential contract loss and market volatility underscore the challenges facing Palantir in the AI landscape. However, the analysts' positive stance may hint at potential opportunities that could boost its stock in the future.

Palantir Stock Slides Amid Market Jitters, AI Contract Concerns